Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564546 | 0.93 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20565241 | 0.93 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20564545 | 0.93 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20564875 | 0.92 | RIPK1 (0.80) | RIPK1 | |
| SCHEMBL21800430 | 0.90 | RIPK1 (0.84) | RIPK1 | |
| SCHEMBL20565660 | 0.89 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL21868487 | 0.88 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL24114666 | 0.88 | RIPK1 (0.76) | RIPK1 | |
| SCHEMBL20565652 | 0.88 | RIPK1 (0.75) | RIPK1 | |
| SCHEMBL21867405 | 0.88 | RIPK1 (0.76) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317776-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20240299412-A1 | DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-f][1,4]OXAZEPINE-9-CARBONITRILE | GENZYME CORPORATION (US) | 2024-09-12 | — | — | US | claimed |
| US-20240100065-A1 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | GENZYME CORPORATION (US) | 2024-03-28 | — | — | US | claimed |
| WO-2024044151-A1 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | GENZYME CORPORATION (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024025817-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5- DIHYDRO-2H-PYRIDO[3,4-F][L,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240025915-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | claimed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006575-A1 | PROCESS FOR PREPARING 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][L,4]OXAZEPINE-9-CARBONITRILE | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240317776-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240317776-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240317776-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | DENALI THERAPEUTICS INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100065-A1 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | RIPK1, HIPK1, RIPK2 | RIPK1 1/4885 |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885 |
| US-20240299412-A1 | DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-f][1,4]OXAZEPINE-9-CARBONITRILE | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885 |
| US-20240317776-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | CACNA1B, CACNA1C, CACNB3 | RIPK1 3642/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885 |
| US-20240025915-A1 | SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE | CACNA1B, CACNA1C, CACNB3 | RIPK1 3642/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.